A Randomized, Single-dose, Two-way Crossover Study to Assess the Bioequivalence of Meloxicam Capsules 15 mg (Mobic(R) Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic(R) Tablets 15 mg) Administered to Healthy Adult Volunteers

Trial Profile

A Randomized, Single-dose, Two-way Crossover Study to Assess the Bioequivalence of Meloxicam Capsules 15 mg (Mobic(R) Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic(R) Tablets 15 mg) Administered to Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Meloxicam (Primary) ; Meloxicam (Primary)
  • Indications Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top